Kymera Therapeutics, Inc.
KYMR
Peringkat dalam Saham
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Harga Saham
$114.06
Kapitalisasi Pasar
$9.38B
Perubahan (1 hari)
5.54%
Perubahan (1 tahun)
88.52%
Negara
US
Perdagangan Kymera Therapeutics, Inc. (KYMR)
Kategori
Healthcare
Laba untuk Kymera Therapeutics, Inc. (KYMR)
Laba pada Jun 2026 TTM: $-299.87M
Menurut laporan keuangan terbaru dari Kymera Therapeutics, Inc., laba saat ini perusahaan adalah $-299.87M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-146.96M, peningkatan dibandingkan laba tahun 2022 sebesar $-154.81M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Kymera Therapeutics, Inc. dari 2018 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-299.87M | 33.96% |
| 2024 | $-223.86M | 52.32% |
| 2023 | $-146.96M | -5.07% |
| 2022 | $-154.81M | 54.47% |
| 2021 | $-100.22M | 119.81% |
| 2020 | $-45.59M | 10.54% |
| 2019 | $-41.25M | 92.14% |
| 2018 | $-21.47M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -1,859.04% |
US
|
|
| $-3.09B | 929.44% |
US
|
|
| $-4.02B | 1,239.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -750.49% |
NL
|
